19 December 2024 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Aim. To analyze the results of modern prevention and treatment strategies applied for bleeding from gastric varices in patients with portal hypertension syndrome.Materials and methods. The study enrolled 276 patients with portal hypertension, including 187 cases of liver cirrhosis and 89 cases of extrahepatic portal hypertension. 24% of the patients with liver cirrhosis were classified as Child-Turcotte-Pugh Class A, 50% as Class B, and 26% as Class C. The portal vein thrombosis was confirmed in 80% of extrahepatic portal hypertension cases, while isolated splenic vein thrombosis was observed in 20%. Varices GOV1 (Sarin classification) were identified in 126 patients (45.7%), GOV2 in 110 patients (39.8%), and IGV-1 in 40 patients (14.5%). The following interventions were performed: endoscopic ligation, endoscopic sclerotherapy, endovascular techniques (transjugular intrahepatic portosystemic shunt, balloon-occluded retrograde transvenous obliteration), laparoscopic gastric devascularization, and distal splenorenal anastomosis.Results. Following endoscopic procedures, recurrence of gastric varices was noted in 20% of cases, and bleeding occurred in 7%. The efficacy of endoscopic treatment amounted to 71%; endoscopic ligation for bleeding from GOV1 varices appeared effective in 94.4% of cases. Early recurrence of bleeding developed in 29.4% of patients. The efficacy of endoscopic sclerotherapy for bleeding from GOV2/IGV1 varices comprised 96.7% with early recurrence occurring in 12.9% of patients. The secondary prevention involved multiple endoscopic interventions that led to complete eradication of gastric varices in 34% of cases with recurrent bleeding noted in 9.3% of patients, while persistent recurrence of gastric varices was observed in 66%. A splenorenal anastomosis provided reliable prevention of recurrent bleedings. No shunt thrombosis or mortality was recorded; however, the incidence of post-shunt encephalopathy comprised 16.5%. Transjugular intrahepatic portosystemic shunt facilitated a significant reduction in portal pressure and the enlargement of esophageal and gastric varices. Post-shunt encephalopathy occurred in 48.6% of patients. In the long-term follow-up, a recurrence of esophagogastric bleeding was recorded in one patient. Laparoscopic azygoportal disconnection contributed to the regression of varices in the esophagus and stomach; however, a recurrence of gastric varices developed in 30% of cases and a recurrence of bleeding in 12.5%.Conclusion. Current medicine obtains a sufficient arsenal of modern methods for the treatment and prevention of bleeding from gastric varices. The choice of treatment and prevention strategies for bleeding in portal hypertension necessitates a differentiated approach, taking into account the etiology and degree of disease decompensation.
3 April 2024 in Grekov's Bulletin of Surgery
Fulminant liver failure (FLF) is a life-threatening condition. The mortality rate among patients with developed fulminant liver failure reaches 70 %. Performing liver transplantation from a posthumous donor for fulminant liver failure, the mortality rate, according to various sources, reaches 25.4 – 38.1 %. Up to 25 % of patients with acute liver failure die on the cadaveric liver waiting list without receiving a transplant. In presented clinical case, a 16-year-old patient developed fulminant liver failure in the absence of chronic diseases. Despite the syndromic therapy, hepatic, kidney and cardiovascular failure progressed. The developed depression of consciousness and respiratory failure required the transfer of the patient to artificial ventilation. Coma and multiple organ failure were diagnosed. As a result of interdepartmental cooperation, the patient urgently underwent liver transplantation from a cadaveric donor. The postoperative period proceeded without complications. On the 36th day, the patient was discharged in satisfactory condition for the outpatient stage of treatment. To date, liver transplantation is the only effective and radical treatment for fulminant liver failure.